2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging
Objective To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype. Methods We developed clinically relevant Patient/Population, Intervention, Comp...
Gespeichert in:
Veröffentlicht in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2022-04, Vol.74 (4), p.570-585 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 585 |
---|---|
container_issue | 4 |
container_start_page | 570 |
container_title | Arthritis & rheumatology (Hoboken, N.J.) |
container_volume | 74 |
creator | Onel, Karen B. Horton, Daniel B. Lovell, Daniel J. Shenoi, Susan Cuello, Carlos A. Angeles‐Han, Sheila T. Becker, Mara L. Cron, Randy Q. Feldman, Brian M. Ferguson, Polly J. Gewanter, Harry Guzman, Jaime Kimura, Yukiko Lee, Tzielan Murphy, Katherine Nigrovic, Peter A. Ombrello, Michael J. Rabinovich, C. Egla Tesher, Melissa Twilt, Marinka Klein‐Gitelman, Marisa Barbar‐Smiley, Fatima Cooper, Ashley M. Edelheit, Barbara Gillispie‐Taylor, Miriah Hays, Kimberly Mannion, Melissa L. Peterson, Rosemary Flanagan, Elaine Saad, Nadine Sullivan, Nancy Szymanski, Ann Marie Trachtman, Rebecca Turgunbaev, Marat Veiga, Keila Turner, Amy S. Reston, James T. |
description | Objective
To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype.
Methods
We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.
Results
Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well‐balanced, age‐appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision‐making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.
Conclusion
This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision‐making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision‐making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver. |
doi_str_mv | 10.1002/art.42036 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10127939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2642930328</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5106-959bbdf8f34cf8474ae35b01dabfb1b82666829ac9d7e30f7c6c872abf5936ab3</originalsourceid><addsrcrecordid>eNp1kc9q3DAQh01pSUKaQ16gCHoq7Cb6Y8tWL2VZ2nRL0sCyOQtZHtsKtuTKcsr2_fpe1cZJaA_VRWLm45sRvyQ5J_iCYEwvlQ8XKcWMv0pOKKN8mVGcvX5-E0GOk7NxvMfxiBxznB0lxyyjjAlOTpLfFFOCVj14o5VFa9d10AByNdq2MPUquM41e3Q1mQo6YwHVzqPQAtp5UKEHGw7st-kBrOkAbSrjBhVao9HKh9abYMaPaAva9ZGtVDDOjo-O784OrfK90ocJkd-14NVgYFygG6jiNgcW3ThrgvPGNgu06fvJml-zZIGUrWJJNbH3NnlTq26Es6f7NLn78nm3_rq8vr3arFfXS50RzJciE2VZ1UXNUl0XaZ4qYFmJSaXKuiRlQTnnBRVKiyoHhutcc13kNHYzwbgq2WnyafYOU9lDpeP3verk4E2v_F46ZeS_HWta2bgHSTChuWAiGt4_Gbz7McEY5L2bvI1LS8pTKhhmtIjUh5nS3o2jh_plBMHykLqMqcvH1CP77u-dXsjnjCNwOQM_Y0L7_5vkarublX8AgIG7zQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642930328</pqid></control><display><type>article</type><title>2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Onel, Karen B. ; Horton, Daniel B. ; Lovell, Daniel J. ; Shenoi, Susan ; Cuello, Carlos A. ; Angeles‐Han, Sheila T. ; Becker, Mara L. ; Cron, Randy Q. ; Feldman, Brian M. ; Ferguson, Polly J. ; Gewanter, Harry ; Guzman, Jaime ; Kimura, Yukiko ; Lee, Tzielan ; Murphy, Katherine ; Nigrovic, Peter A. ; Ombrello, Michael J. ; Rabinovich, C. Egla ; Tesher, Melissa ; Twilt, Marinka ; Klein‐Gitelman, Marisa ; Barbar‐Smiley, Fatima ; Cooper, Ashley M. ; Edelheit, Barbara ; Gillispie‐Taylor, Miriah ; Hays, Kimberly ; Mannion, Melissa L. ; Peterson, Rosemary ; Flanagan, Elaine ; Saad, Nadine ; Sullivan, Nancy ; Szymanski, Ann Marie ; Trachtman, Rebecca ; Turgunbaev, Marat ; Veiga, Keila ; Turner, Amy S. ; Reston, James T.</creator><creatorcontrib>Onel, Karen B. ; Horton, Daniel B. ; Lovell, Daniel J. ; Shenoi, Susan ; Cuello, Carlos A. ; Angeles‐Han, Sheila T. ; Becker, Mara L. ; Cron, Randy Q. ; Feldman, Brian M. ; Ferguson, Polly J. ; Gewanter, Harry ; Guzman, Jaime ; Kimura, Yukiko ; Lee, Tzielan ; Murphy, Katherine ; Nigrovic, Peter A. ; Ombrello, Michael J. ; Rabinovich, C. Egla ; Tesher, Melissa ; Twilt, Marinka ; Klein‐Gitelman, Marisa ; Barbar‐Smiley, Fatima ; Cooper, Ashley M. ; Edelheit, Barbara ; Gillispie‐Taylor, Miriah ; Hays, Kimberly ; Mannion, Melissa L. ; Peterson, Rosemary ; Flanagan, Elaine ; Saad, Nadine ; Sullivan, Nancy ; Szymanski, Ann Marie ; Trachtman, Rebecca ; Turgunbaev, Marat ; Veiga, Keila ; Turner, Amy S. ; Reston, James T.</creatorcontrib><description>Objective
To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype.
Methods
We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.
Results
Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well‐balanced, age‐appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision‐making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.
Conclusion
This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision‐making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision‐making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.</description><identifier>ISSN: 2326-5191</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.42036</identifier><identifier>PMID: 35233961</identifier><language>eng</language><publisher>Boston, USA: Wiley Periodicals, Inc</publisher><subject>Antirheumatic Agents - therapeutic use ; Arthritis ; Arthritis, Juvenile - drug therapy ; Arthritis, Juvenile - therapy ; Caregivers ; Decision making ; Glucocorticoids - therapeutic use ; Humans ; Immunization ; Literature reviews ; Medical imaging ; Monitoring ; Patients ; Phenotypes ; Polyarthritis ; Quality of Life ; Rheumatology ; Sacroiliitis ; Telemedicine ; United States ; Uveitis ; Uveitis - drug therapy</subject><ispartof>Arthritis & rheumatology (Hoboken, N.J.), 2022-04, Vol.74 (4), p.570-585</ispartof><rights>2022 American College of Rheumatology</rights><rights>2022 American College of Rheumatology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5106-959bbdf8f34cf8474ae35b01dabfb1b82666829ac9d7e30f7c6c872abf5936ab3</citedby><cites>FETCH-LOGICAL-c5106-959bbdf8f34cf8474ae35b01dabfb1b82666829ac9d7e30f7c6c872abf5936ab3</cites><orcidid>0000-0003-1604-0130 ; 0000-0002-0959-2343 ; 0000-0002-8855-845X ; 0000-0002-2216-970X ; 0000-0001-7132-3390 ; 0000-0001-8508-3578 ; 0000-0003-2661-3086 ; 0000-0002-6322-1375 ; 0000-0002-8634-9443 ; 0000-0002-2495-594X ; 0000-0001-7695-2022 ; 0000-0002-1238-5361 ; 0000-0002-1831-1339 ; 0000-0001-8977-2581 ; 0000-0003-3322-4089 ; 0000-0002-9552-6464</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.42036$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.42036$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35233961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onel, Karen B.</creatorcontrib><creatorcontrib>Horton, Daniel B.</creatorcontrib><creatorcontrib>Lovell, Daniel J.</creatorcontrib><creatorcontrib>Shenoi, Susan</creatorcontrib><creatorcontrib>Cuello, Carlos A.</creatorcontrib><creatorcontrib>Angeles‐Han, Sheila T.</creatorcontrib><creatorcontrib>Becker, Mara L.</creatorcontrib><creatorcontrib>Cron, Randy Q.</creatorcontrib><creatorcontrib>Feldman, Brian M.</creatorcontrib><creatorcontrib>Ferguson, Polly J.</creatorcontrib><creatorcontrib>Gewanter, Harry</creatorcontrib><creatorcontrib>Guzman, Jaime</creatorcontrib><creatorcontrib>Kimura, Yukiko</creatorcontrib><creatorcontrib>Lee, Tzielan</creatorcontrib><creatorcontrib>Murphy, Katherine</creatorcontrib><creatorcontrib>Nigrovic, Peter A.</creatorcontrib><creatorcontrib>Ombrello, Michael J.</creatorcontrib><creatorcontrib>Rabinovich, C. Egla</creatorcontrib><creatorcontrib>Tesher, Melissa</creatorcontrib><creatorcontrib>Twilt, Marinka</creatorcontrib><creatorcontrib>Klein‐Gitelman, Marisa</creatorcontrib><creatorcontrib>Barbar‐Smiley, Fatima</creatorcontrib><creatorcontrib>Cooper, Ashley M.</creatorcontrib><creatorcontrib>Edelheit, Barbara</creatorcontrib><creatorcontrib>Gillispie‐Taylor, Miriah</creatorcontrib><creatorcontrib>Hays, Kimberly</creatorcontrib><creatorcontrib>Mannion, Melissa L.</creatorcontrib><creatorcontrib>Peterson, Rosemary</creatorcontrib><creatorcontrib>Flanagan, Elaine</creatorcontrib><creatorcontrib>Saad, Nadine</creatorcontrib><creatorcontrib>Sullivan, Nancy</creatorcontrib><creatorcontrib>Szymanski, Ann Marie</creatorcontrib><creatorcontrib>Trachtman, Rebecca</creatorcontrib><creatorcontrib>Turgunbaev, Marat</creatorcontrib><creatorcontrib>Veiga, Keila</creatorcontrib><creatorcontrib>Turner, Amy S.</creatorcontrib><creatorcontrib>Reston, James T.</creatorcontrib><title>2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging</title><title>Arthritis & rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheumatol</addtitle><description>Objective
To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype.
Methods
We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.
Results
Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well‐balanced, age‐appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision‐making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.
Conclusion
This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision‐making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision‐making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.</description><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis</subject><subject>Arthritis, Juvenile - drug therapy</subject><subject>Arthritis, Juvenile - therapy</subject><subject>Caregivers</subject><subject>Decision making</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunization</subject><subject>Literature reviews</subject><subject>Medical imaging</subject><subject>Monitoring</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>Polyarthritis</subject><subject>Quality of Life</subject><subject>Rheumatology</subject><subject>Sacroiliitis</subject><subject>Telemedicine</subject><subject>United States</subject><subject>Uveitis</subject><subject>Uveitis - drug therapy</subject><issn>2326-5191</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9q3DAQh01pSUKaQ16gCHoq7Cb6Y8tWL2VZ2nRL0sCyOQtZHtsKtuTKcsr2_fpe1cZJaA_VRWLm45sRvyQ5J_iCYEwvlQ8XKcWMv0pOKKN8mVGcvX5-E0GOk7NxvMfxiBxznB0lxyyjjAlOTpLfFFOCVj14o5VFa9d10AByNdq2MPUquM41e3Q1mQo6YwHVzqPQAtp5UKEHGw7st-kBrOkAbSrjBhVao9HKh9abYMaPaAva9ZGtVDDOjo-O784OrfK90ocJkd-14NVgYFygG6jiNgcW3ThrgvPGNgu06fvJml-zZIGUrWJJNbH3NnlTq26Es6f7NLn78nm3_rq8vr3arFfXS50RzJciE2VZ1UXNUl0XaZ4qYFmJSaXKuiRlQTnnBRVKiyoHhutcc13kNHYzwbgq2WnyafYOU9lDpeP3verk4E2v_F46ZeS_HWta2bgHSTChuWAiGt4_Gbz7McEY5L2bvI1LS8pTKhhmtIjUh5nS3o2jh_plBMHykLqMqcvH1CP77u-dXsjnjCNwOQM_Y0L7_5vkarublX8AgIG7zQ</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Onel, Karen B.</creator><creator>Horton, Daniel B.</creator><creator>Lovell, Daniel J.</creator><creator>Shenoi, Susan</creator><creator>Cuello, Carlos A.</creator><creator>Angeles‐Han, Sheila T.</creator><creator>Becker, Mara L.</creator><creator>Cron, Randy Q.</creator><creator>Feldman, Brian M.</creator><creator>Ferguson, Polly J.</creator><creator>Gewanter, Harry</creator><creator>Guzman, Jaime</creator><creator>Kimura, Yukiko</creator><creator>Lee, Tzielan</creator><creator>Murphy, Katherine</creator><creator>Nigrovic, Peter A.</creator><creator>Ombrello, Michael J.</creator><creator>Rabinovich, C. Egla</creator><creator>Tesher, Melissa</creator><creator>Twilt, Marinka</creator><creator>Klein‐Gitelman, Marisa</creator><creator>Barbar‐Smiley, Fatima</creator><creator>Cooper, Ashley M.</creator><creator>Edelheit, Barbara</creator><creator>Gillispie‐Taylor, Miriah</creator><creator>Hays, Kimberly</creator><creator>Mannion, Melissa L.</creator><creator>Peterson, Rosemary</creator><creator>Flanagan, Elaine</creator><creator>Saad, Nadine</creator><creator>Sullivan, Nancy</creator><creator>Szymanski, Ann Marie</creator><creator>Trachtman, Rebecca</creator><creator>Turgunbaev, Marat</creator><creator>Veiga, Keila</creator><creator>Turner, Amy S.</creator><creator>Reston, James T.</creator><general>Wiley Periodicals, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1604-0130</orcidid><orcidid>https://orcid.org/0000-0002-0959-2343</orcidid><orcidid>https://orcid.org/0000-0002-8855-845X</orcidid><orcidid>https://orcid.org/0000-0002-2216-970X</orcidid><orcidid>https://orcid.org/0000-0001-7132-3390</orcidid><orcidid>https://orcid.org/0000-0001-8508-3578</orcidid><orcidid>https://orcid.org/0000-0003-2661-3086</orcidid><orcidid>https://orcid.org/0000-0002-6322-1375</orcidid><orcidid>https://orcid.org/0000-0002-8634-9443</orcidid><orcidid>https://orcid.org/0000-0002-2495-594X</orcidid><orcidid>https://orcid.org/0000-0001-7695-2022</orcidid><orcidid>https://orcid.org/0000-0002-1238-5361</orcidid><orcidid>https://orcid.org/0000-0002-1831-1339</orcidid><orcidid>https://orcid.org/0000-0001-8977-2581</orcidid><orcidid>https://orcid.org/0000-0003-3322-4089</orcidid><orcidid>https://orcid.org/0000-0002-9552-6464</orcidid></search><sort><creationdate>202204</creationdate><title>2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging</title><author>Onel, Karen B. ; Horton, Daniel B. ; Lovell, Daniel J. ; Shenoi, Susan ; Cuello, Carlos A. ; Angeles‐Han, Sheila T. ; Becker, Mara L. ; Cron, Randy Q. ; Feldman, Brian M. ; Ferguson, Polly J. ; Gewanter, Harry ; Guzman, Jaime ; Kimura, Yukiko ; Lee, Tzielan ; Murphy, Katherine ; Nigrovic, Peter A. ; Ombrello, Michael J. ; Rabinovich, C. Egla ; Tesher, Melissa ; Twilt, Marinka ; Klein‐Gitelman, Marisa ; Barbar‐Smiley, Fatima ; Cooper, Ashley M. ; Edelheit, Barbara ; Gillispie‐Taylor, Miriah ; Hays, Kimberly ; Mannion, Melissa L. ; Peterson, Rosemary ; Flanagan, Elaine ; Saad, Nadine ; Sullivan, Nancy ; Szymanski, Ann Marie ; Trachtman, Rebecca ; Turgunbaev, Marat ; Veiga, Keila ; Turner, Amy S. ; Reston, James T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5106-959bbdf8f34cf8474ae35b01dabfb1b82666829ac9d7e30f7c6c872abf5936ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis</topic><topic>Arthritis, Juvenile - drug therapy</topic><topic>Arthritis, Juvenile - therapy</topic><topic>Caregivers</topic><topic>Decision making</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunization</topic><topic>Literature reviews</topic><topic>Medical imaging</topic><topic>Monitoring</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>Polyarthritis</topic><topic>Quality of Life</topic><topic>Rheumatology</topic><topic>Sacroiliitis</topic><topic>Telemedicine</topic><topic>United States</topic><topic>Uveitis</topic><topic>Uveitis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onel, Karen B.</creatorcontrib><creatorcontrib>Horton, Daniel B.</creatorcontrib><creatorcontrib>Lovell, Daniel J.</creatorcontrib><creatorcontrib>Shenoi, Susan</creatorcontrib><creatorcontrib>Cuello, Carlos A.</creatorcontrib><creatorcontrib>Angeles‐Han, Sheila T.</creatorcontrib><creatorcontrib>Becker, Mara L.</creatorcontrib><creatorcontrib>Cron, Randy Q.</creatorcontrib><creatorcontrib>Feldman, Brian M.</creatorcontrib><creatorcontrib>Ferguson, Polly J.</creatorcontrib><creatorcontrib>Gewanter, Harry</creatorcontrib><creatorcontrib>Guzman, Jaime</creatorcontrib><creatorcontrib>Kimura, Yukiko</creatorcontrib><creatorcontrib>Lee, Tzielan</creatorcontrib><creatorcontrib>Murphy, Katherine</creatorcontrib><creatorcontrib>Nigrovic, Peter A.</creatorcontrib><creatorcontrib>Ombrello, Michael J.</creatorcontrib><creatorcontrib>Rabinovich, C. Egla</creatorcontrib><creatorcontrib>Tesher, Melissa</creatorcontrib><creatorcontrib>Twilt, Marinka</creatorcontrib><creatorcontrib>Klein‐Gitelman, Marisa</creatorcontrib><creatorcontrib>Barbar‐Smiley, Fatima</creatorcontrib><creatorcontrib>Cooper, Ashley M.</creatorcontrib><creatorcontrib>Edelheit, Barbara</creatorcontrib><creatorcontrib>Gillispie‐Taylor, Miriah</creatorcontrib><creatorcontrib>Hays, Kimberly</creatorcontrib><creatorcontrib>Mannion, Melissa L.</creatorcontrib><creatorcontrib>Peterson, Rosemary</creatorcontrib><creatorcontrib>Flanagan, Elaine</creatorcontrib><creatorcontrib>Saad, Nadine</creatorcontrib><creatorcontrib>Sullivan, Nancy</creatorcontrib><creatorcontrib>Szymanski, Ann Marie</creatorcontrib><creatorcontrib>Trachtman, Rebecca</creatorcontrib><creatorcontrib>Turgunbaev, Marat</creatorcontrib><creatorcontrib>Veiga, Keila</creatorcontrib><creatorcontrib>Turner, Amy S.</creatorcontrib><creatorcontrib>Reston, James T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onel, Karen B.</au><au>Horton, Daniel B.</au><au>Lovell, Daniel J.</au><au>Shenoi, Susan</au><au>Cuello, Carlos A.</au><au>Angeles‐Han, Sheila T.</au><au>Becker, Mara L.</au><au>Cron, Randy Q.</au><au>Feldman, Brian M.</au><au>Ferguson, Polly J.</au><au>Gewanter, Harry</au><au>Guzman, Jaime</au><au>Kimura, Yukiko</au><au>Lee, Tzielan</au><au>Murphy, Katherine</au><au>Nigrovic, Peter A.</au><au>Ombrello, Michael J.</au><au>Rabinovich, C. Egla</au><au>Tesher, Melissa</au><au>Twilt, Marinka</au><au>Klein‐Gitelman, Marisa</au><au>Barbar‐Smiley, Fatima</au><au>Cooper, Ashley M.</au><au>Edelheit, Barbara</au><au>Gillispie‐Taylor, Miriah</au><au>Hays, Kimberly</au><au>Mannion, Melissa L.</au><au>Peterson, Rosemary</au><au>Flanagan, Elaine</au><au>Saad, Nadine</au><au>Sullivan, Nancy</au><au>Szymanski, Ann Marie</au><au>Trachtman, Rebecca</au><au>Turgunbaev, Marat</au><au>Veiga, Keila</au><au>Turner, Amy S.</au><au>Reston, James T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging</atitle><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheumatol</addtitle><date>2022-04</date><risdate>2022</risdate><volume>74</volume><issue>4</issue><spage>570</spage><epage>585</epage><pages>570-585</pages><issn>2326-5191</issn><eissn>2326-5205</eissn><abstract>Objective
To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype.
Methods
We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.
Results
Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well‐balanced, age‐appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision‐making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.
Conclusion
This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision‐making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision‐making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.</abstract><cop>Boston, USA</cop><pub>Wiley Periodicals, Inc</pub><pmid>35233961</pmid><doi>10.1002/art.42036</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0003-1604-0130</orcidid><orcidid>https://orcid.org/0000-0002-0959-2343</orcidid><orcidid>https://orcid.org/0000-0002-8855-845X</orcidid><orcidid>https://orcid.org/0000-0002-2216-970X</orcidid><orcidid>https://orcid.org/0000-0001-7132-3390</orcidid><orcidid>https://orcid.org/0000-0001-8508-3578</orcidid><orcidid>https://orcid.org/0000-0003-2661-3086</orcidid><orcidid>https://orcid.org/0000-0002-6322-1375</orcidid><orcidid>https://orcid.org/0000-0002-8634-9443</orcidid><orcidid>https://orcid.org/0000-0002-2495-594X</orcidid><orcidid>https://orcid.org/0000-0001-7695-2022</orcidid><orcidid>https://orcid.org/0000-0002-1238-5361</orcidid><orcidid>https://orcid.org/0000-0002-1831-1339</orcidid><orcidid>https://orcid.org/0000-0001-8977-2581</orcidid><orcidid>https://orcid.org/0000-0003-3322-4089</orcidid><orcidid>https://orcid.org/0000-0002-9552-6464</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2326-5191 |
ispartof | Arthritis & rheumatology (Hoboken, N.J.), 2022-04, Vol.74 (4), p.570-585 |
issn | 2326-5191 2326-5205 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10127939 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
subjects | Antirheumatic Agents - therapeutic use Arthritis Arthritis, Juvenile - drug therapy Arthritis, Juvenile - therapy Caregivers Decision making Glucocorticoids - therapeutic use Humans Immunization Literature reviews Medical imaging Monitoring Patients Phenotypes Polyarthritis Quality of Life Rheumatology Sacroiliitis Telemedicine United States Uveitis Uveitis - drug therapy |
title | 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T10%3A28%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=2021%20American%20College%20of%20Rheumatology%20Guideline%20for%20the%20Treatment%20of%20Juvenile%20Idiopathic%20Arthritis:%20Recommendations%20for%20Nonpharmacologic%20Therapies,%20Medication%20Monitoring,%20Immunizations,%20and%20Imaging&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Onel,%20Karen%20B.&rft.date=2022-04&rft.volume=74&rft.issue=4&rft.spage=570&rft.epage=585&rft.pages=570-585&rft.issn=2326-5191&rft.eissn=2326-5205&rft_id=info:doi/10.1002/art.42036&rft_dat=%3Cproquest_pubme%3E2642930328%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642930328&rft_id=info:pmid/35233961&rfr_iscdi=true |